These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15372067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory element.
    Werner M, Kraunus J, Baum C, Brocker T.
    Gene Ther; 2004 Jun; 11(12):992-1000. PubMed ID: 15029232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
    Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA, Baum C.
    Mol Ther; 2006 Feb; 13(2):391-400. PubMed ID: 16226060
    [Abstract] [Full Text] [Related]

  • 6. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
    Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R, Baum C, Bohne J.
    Gene Ther; 2006 Nov; 13(21):1524-33. PubMed ID: 16763662
    [Abstract] [Full Text] [Related]

  • 7. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.
    Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E, Ryser MF, Haria S, Thrasher AJ, Baum C, Brenner S, Grez M.
    Gene Ther; 2009 Jan; 16(1):111-8. PubMed ID: 18784749
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Construction of retroviral vectors with enhanced efficiency of transgene expression.
    Hahm SH, Yi Y, Lee DK, Noh MJ, Yun L, Hwang S, Lee KH.
    J Virol Methods; 2004 Nov; 121(2):127-36. PubMed ID: 15381349
    [Abstract] [Full Text] [Related]

  • 10. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression.
    Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D, Giroglou T.
    Gene Ther; 2006 Apr; 13(7):641-5. PubMed ID: 16355114
    [Abstract] [Full Text] [Related]

  • 11. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
    Brandtner EM, Kodajova P, Hlavaty J, Jandl G, Tabotta W, Salmons B, Günzburg WH, Hohenadl C.
    J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
    [Abstract] [Full Text] [Related]

  • 12. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors.
    Hlavaty J, Schittmayer M, Stracke A, Jandl G, Knapp E, Felber BK, Salmons B, Günzburg WH, Renner M.
    Virology; 2005 Oct 10; 341(1):1-11. PubMed ID: 16054668
    [Abstract] [Full Text] [Related]

  • 13. Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer.
    O'Rourke JP, Olsen JC, Bunnell BA.
    Gene Ther; 2005 Jan 10; 12(1):22-9. PubMed ID: 15550928
    [Abstract] [Full Text] [Related]

  • 14. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.
    Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J.
    J Gene Med; 2005 Jun 10; 7(6):803-17. PubMed ID: 15655804
    [Abstract] [Full Text] [Related]

  • 15. T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.
    Zhao-Emonet JC, Marodon G, Pioche-Durieu C, Cosset FL, Klatzmann D.
    J Gene Med; 2000 Jun 10; 2(6):416-25. PubMed ID: 11199262
    [Abstract] [Full Text] [Related]

  • 16. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors.
    Schambach A, Wodrich H, Hildinger M, Bohne J, Kräusslich HG, Baum C.
    Mol Ther; 2000 Nov 10; 2(5):435-45. PubMed ID: 11082317
    [Abstract] [Full Text] [Related]

  • 17. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
    Avedillo Díez I, Zychlinski D, Coci EG, Galla M, Modlich U, Dewey RA, Schwarzer A, Maetzig T, Mpofu N, Jaeckel E, Boztug K, Baum C, Klein C, Schambach A.
    Mol Pharm; 2011 Oct 03; 8(5):1525-37. PubMed ID: 21851067
    [Abstract] [Full Text] [Related]

  • 18. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.
    Zanta-Boussif MA, Charrier S, Brice-Ouzet A, Martin S, Opolon P, Thrasher AJ, Hope TJ, Galy A.
    Gene Ther; 2009 May 03; 16(5):605-19. PubMed ID: 19262615
    [Abstract] [Full Text] [Related]

  • 19. Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes.
    Unsinger J, Kröger A, Hauser H, Wirth D.
    Mol Ther; 2001 Nov 03; 4(5):484-9. PubMed ID: 11708885
    [Abstract] [Full Text] [Related]

  • 20. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells.
    Hildinger M, Eckert HG, Schilz AJ, John J, Ostertag W, Baum C.
    Gene Ther; 1998 Nov 03; 5(11):1575-9. PubMed ID: 9930313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.